DanDi Bioscience

http://m.biospectator.com/view/news_view.php?varAtcId=10260  

This post has been translated from the original article dated 5/6/2020. 

Dandibio announced on the 6th that the peptide-based multidrug-resistant Gram-negative bacteria (DD-S052) under development has been xxxxselected as an "unresolved treatment challenge technology development project" of the Ministry of Health and Welfare's infectious disease prevention treatment technology development project. As a result, Dandibio received a total of 2.05 billion won for two years and nine months to accelerate the development of super bacteria treatments. Park Young-min, CEO of Dandibio, explained, "The project aims to complete non-clinical trials of the multi-drug resistant gram-negative bacteria pipeline within three years and complete the U.S. Food and Drug Administration (FDA) clinical trial plan approval (IND) process." The Ministry of Health and Welfare's project aims to support candidate materials for infectious disease treatment at a global level from the stage of new drug development to the time of approval of clinical trial plans. From the beginning of the project to the second year, single and combined administration of multidrug-resistant gram-negative bacteria separated from clinical samples will evaluate the efficacy and safety of antibiotic candidates and identify the mechanism of antibacterial action. It also completes the GLP toxicity test and pharmacokinetic evaluation of antibiotic candidates and optimizes the production process of drugs for clinical trials. In the final third year, it consists of establishing the test design necessary for FDA approval of phase 1 clinical trials and receiving INDs. Yoon Young-kyung, a professor of infectious medicine at Korea University, is in charge of the project, and Kim Yang-mi, a professor of protein tertiary structure and peptide development, and Jeong In-deok, vice president of Dandibio, are in charge of detailed research. In particular, Gram-negative bacteria commonly cause severe schistosis or shock during shingles of various causes, and as the use of antibiotics increases, resistant bacteria infection continues to occur. Dandibio's DD-S052 is a low-toxic, low-molecular antibiotic candidate with a double function that directly kills antibiotic-resistant bacteria and inhibits the secretion of excessive inflammatory cytokines, one of the causes of sepsis, by removing endotoxins derived from Gram-negative bacteria. Currently, antibacterial activity against various Gram-negative bacteria has been confirmed, and excellent therapeutic effects have been confirmed in efficacy tests on carbapenem-resistant strains of self-infected animal models. CEO Park said, "Dandi Bioscience will establish HBS (HLB Bioeco-System) with its largest shareholder Next Science, HLB and HLB Life Sciences with global clinical experience, and Immunomic Theraputics of the United States to seek shared growth through organic cooperation between companies." Meanwhile, Dandibio announced that it signed a "memorandum of understanding for the development of new sepsis drugs and mutual cooperation" with Q Best Bio, a non-clinical CRO in Korea, to verify sepsis treatments, the leading pipeline, and enter clinical trials in the U.S.